durata therapeutics presenting two abstracts concerning dalbavancin at idweek 2012

Business Wire Durata Therapeutics Presenting Two Abstracts Concerning Dalbavancin at IDWeek 2012 Press Release
October 4, 2012

MORRISTOWN, N.J.--(BUSINESS WIRE)--Durata Therapeutics (NASDAQ: DRTX) today announced that data from two clinical trials of its lead product candidate, dalbavancin, will be presented in two posters during the IDWeek conference in San Diego from October 17-21, 2012. IDWeek is the first-ever combined meeting of four prestigious societies: the Infectious Diseases Society of America (IDSA), the Society for Healthcare Epidemiology of America (SHEA), the HIV Medicine Association (HIVMA), and the Pediatric Infectious Diseases Society (PIDS). Durata is presenting the data during the Novel Antimicrobial Agents session on Saturday, October 20, 12:30 – 2:00 p.m. PT in Halls F-H: -- A Study to Assess Skin Lesion Measurement Techniques Related to Acute Bacterial Skin and Skin Structure Infections (Dunne, et al). Abstract Number: 36757. Presenting author: Michael Dunne, MD -- The effect of lung surfactant on the in vitro activity of dalbavancin against Staphylococcus aureus and Streptococcus pneumoniae (Dunne, et al). Abstract Number: 36184. Presenting authors: Michael Dunne, MD and Laura Koeth Durata will display the two posters from Thursday, October 18 at 9:30 a.m. until Saturday, October 20 at 6:00 p.m. About Dalbavancin Dalbavancin is an intravenous antibiotic product candidate under investigation for once-weekly dosing, which we believe may facilitate the treatment of patients with ABSSSI in both the in-patient and out-patient settings, potentially reducing the length of a patient’s hospital stay or avoiding hospital admission altogether, with an impact on the overall cost of care for these patients. About Durata Therapeutics Durata Therapeutics is a pharmaceutical company focused on the development and commercialization of novel therapeutics for patients with infectious diseases and acute illnesses. Durata is currently enrolling and dosing patients in two global Phase 3 clinical trials with its lead product candidate, dalbavancin, for the treatment of patients with acute bacterial skin and skin structure infections, or ABSSSI. Forward-looking statements Any statements in this press release about Durata’s future expectations, plans and prospects constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, as amended. Actual results may differ materially from those indicated by such forward-looking statements. Durata anticipates that subsequent events and developments will cause its views to change. However, while Durata may elect to update these forward-looking statements at some point in the future, Durata specifically disclaims any obligation to do so. Contacts Media Relations Contact White Oak Communications, Inc. Jed Weiner, (847) 392-4186 jed.weiner@comcast.net or Investor Relations Contacts Durata Therapeutics Corey Fishman, (973) 993-4865 Chief Operating Officer and Chief Financial Officer cfishman@duratatherapeutics.com or The Trout Group LLC Lee M. Stern, (646) 378-2922 lstern@troutgroup.com www.troutgroup.com

Most Read: Latest Added Related Topics White House LGBT Conference on HIV/AIDS UNITED STATES: White House in Atlanta: LGBT AIDS Conference No more single-theme conferences: global HIV prevention conference planned FHI 360 Senior Scientist Lut Van Damme Receives International Microbicide Conference Lifetime Achievement Award Photographs from A Day with HIV Now Online Equatorial Guinea Ministry of Health and Social Welfare and UNICEF Refute Erroneous AIDS Prevalence Figures Bulgaria urges Libya to investigate AIDS nurses case Engineers enter fight against AIDS in Africa Gilead’s Complera® Non-Inferior to Atripla® Among Treatment-Naive HIV Patients UN chief Ban calls world leaders to end Aids by 2020 ARIZONA: Routine Skin Testing Available Again at Tuberculosis Clinic Starting May 20 NORTH DAKOTA: Officials: 26 Tuberculosis Cases from Grand Forks Outbreak AUSTRALIA: HIV Rates Triple in the Northern Territory in Just 12 Months ARIZONA: Parsons Foundation Gives $3 Million to Southwest Center for HIV/AIDS UNITED STATES: Triple Therapy for Hepatitis C is Effective After Liver Transplantation, but Side-Effects Are Common CANADA: Nunavut Uses Comic Book to Do Sex Education NEW HAMPSHIRE: State Health Officials Urge Hepatitis Testing UNITED STATES: Hepatitis C Testing for People Born Between 1945 and 1965 People with HIV pay more for life insurance – if they can get it (South Africa)Uganda: Gov't Urged to Levy a Tax On Alcohol to Fund HIV Sangamo BioSciences Presents Clinical Data Demonstrating HIV Reservoir Reduction in HIV-Infected Subjects Treated with ZFP Therapeutic(R), SB-728-T THE BAHAMAS: U.S. Charge d'Affaires Presents $14,000 to Bahamian Organizations to Promote HIV/AIDS Awareness 2012 US medicine sales show shifts by drug type GLOBAL: Medical News Self-Testing Improves HIV Screening, Concerns Persist MINNESOTA: Boynton to Examine International Student Health Concerns Steroids: Concern over illegal production increase in Wales ILLINOIS Ocular Tuberculosis Presents a Diagnostic Challenge FDA rejects two Gilead HIV drugs as standalone products Inhibikase Therapeutics to present at 5th International Congress on Polyomaviruses and Human Diseases - May 11, 2013 Grand Hotel Bristol, Stresa, Italy 2012 Minnesota HIV report shows increase in new cases
Copyright © 2012 -Business Wire, Publisher. All rights reserved to Business Wire.Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through the Business Wire, permissions Desk, Business Wire, 1185 Avenue of the Americas, 3rd Floor, New York, NY 10036; Tel: (212) 575-8822; FAX: (212) 575-1854. Business Wire. Information in this article was accurate in October 4, 2012. The state of the art may have changed since the publication date. This material is designed to support, not replace, the relationship that exists between you and your doctor. Always discuss treatment options with a doctor who specializes in treating HIV.